APLS Relative Valuation
APLS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APLS is overvalued; if below, it's undervalued.
Historical Valuation
Apellis Pharmaceuticals Inc (APLS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -26.16. The fair price of Apellis Pharmaceuticals Inc (APLS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：22.19
Fair
-14.92
PE
1Y
3Y
5Y
Trailing
Forward
-18.09
EV/EBITDA
Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBITDA of -18.09. The 5-year average EV/EBITDA is -19.48. The thresholds are as follows: Strongly Undervalued below -278.48, Undervalued between -278.48 and -148.98, Fairly Valued between 110.02 and -148.98, Overvalued between 110.02 and 239.52, and Strongly Overvalued above 239.52. The current Forward EV/EBITDA of -18.09 falls within the Historic Trend Line -Fairly Valued range.
-16.69
EV/EBIT
Apellis Pharmaceuticals Inc. (APLS) has a current EV/EBIT of -16.69. The 5-year average EV/EBIT is -58.83. The thresholds are as follows: Strongly Undervalued below -798.06, Undervalued between -798.06 and -428.45, Fairly Valued between 310.78 and -428.45, Overvalued between 310.78 and 680.39, and Strongly Overvalued above 680.39. The current Forward EV/EBIT of -16.69 falls within the Historic Trend Line -Fairly Valued range.
3.24
PS
Apellis Pharmaceuticals Inc. (APLS) has a current PS of 3.24. The 5-year average PS is 36.37. The thresholds are as follows: Strongly Undervalued below -71.09, Undervalued between -71.09 and -17.36, Fairly Valued between 90.10 and -17.36, Overvalued between 90.10 and 143.83, and Strongly Overvalued above 143.83. The current Forward PS of 3.24 falls within the Historic Trend Line -Fairly Valued range.
-82.57
P/OCF
Apellis Pharmaceuticals Inc. (APLS) has a current P/OCF of -82.57. The 5-year average P/OCF is -60.05. The thresholds are as follows: Strongly Undervalued below -350.40, Undervalued between -350.40 and -205.22, Fairly Valued between 85.13 and -205.22, Overvalued between 85.13 and 230.31, and Strongly Overvalued above 230.31. The current Forward P/OCF of -82.57 falls within the Historic Trend Line -Fairly Valued range.
138.73
P/FCF
Apellis Pharmaceuticals Inc. (APLS) has a current P/FCF of 138.73. The 5-year average P/FCF is -9.90. The thresholds are as follows: Strongly Undervalued below -132.35, Undervalued between -132.35 and -71.12, Fairly Valued between 51.32 and -71.12, Overvalued between 51.32 and 112.55, and Strongly Overvalued above 112.55. The current Forward P/FCF of 138.73 falls within the Strongly Overvalued range.
Apellis Pharmaceuticals Inc (APLS) has a current Price-to-Book (P/B) ratio of 7.00. Compared to its 3-year average P/B ratio of 20.88 , the current P/B ratio is approximately -66.49% higher. Relative to its 5-year average P/B ratio of 16.44, the current P/B ratio is about -57.44% higher. Apellis Pharmaceuticals Inc (APLS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.66%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.23% , the current FCF yield is about -100.00% lower.
7.00
P/B
Median3y
20.88
Median5y
16.44
2.92
FCF Yield
Median3y
-6.66
Median5y
-7.23
Competitors Valuation Multiple
The average P/S ratio for APLS's competitors is , providing a benchmark for relative valuation. Apellis Pharmaceuticals Inc Corp (APLS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 132.98%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APLS decreased by 30.46% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 196.83M to 458.58M.
The secondary factor is the P/E Change, contributed 97.71%to the performance.
Overall, the performance of APLS in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Apellis Pharmaceuticals Inc (APLS) currently overvalued or undervalued?
What is Apellis Pharmaceuticals Inc (APLS) fair value?
How does APLS's valuation metrics compare to the industry average?
What is the current P/B ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 05 2025?
What is the current FCF Yield for Apellis Pharmaceuticals Inc (APLS) as of Dec 05 2025?
What is the current Forward P/E ratio for Apellis Pharmaceuticals Inc (APLS) as of Dec 05 2025?